Koichi Matsuo

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7643321/publications.pdf

Version: 2024-02-01

		1937685	1720034
9	97	4	7
papers	citations	h-index	g-index

10	10	10	176
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Association between disease severity according to â€œMN criteriaâ€•and 30-day mortality in patients with Clostridioides difficile infection. Journal of Infection and Chemotherapy, 2022, , .	1.7	1
2	Estimating the effect of optimizing anticancer drug vials on medical costs in Japan based on the data from a cancer hospital. BMC Health Services Research, 2020, 20, 1017.	2.2	5
3	Inappropriate direct oral anticoagulant dosing in atrial fibrillation patients is associated with prescriptions for outpatients rather than inpatients: a single-center retrospective cohort study. Journal of Pharmaceutical Health Care and Sciences, 2020, 6, 2.	1.0	19
4	Relationship between Adverse Events and AUC in Japanese Patients with Multiple Myeloma Receiving High-dose Melphalan. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), 2020, 46, 396-402.	0.1	0
5	Change in the Antimicrobial Resistance Profile of Extended-Spectrum Î²-Lactamase-Producing Escherichia coli. Journal of Clinical Medicine Research, 2019, 11, 635-641.	1.2	10
6	Association between medication adherence and illness perceptions in atrial fibrillation patients treated with direct oral anticoagulants: An observational cross-sectional pilot study. PLoS ONE, 2018, 13, e0204814.	2.5	43
7	Population Pharmacodynamic Analysis for Exploration of the Factors Affecting Serum Uric Acid Levels in Hyperuricemic Patients who are Switched from Allopurinol to Febuxostat. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), 2018, 44, 205-214.	0.1	0
8	Population Pharmacodynamic Analysis of Allopurinol Based on Electronic Medical Records. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), 2017, 43, 630-639.	0.1	0
9	Recombinant human soluble thrombomodulin ameliorates cerebral ischemic injury through a high-mobility group box 1 inhibitory mechanism without hemorrhagic complications in mice. Journal of the Neurological Sciences, 2016, 362, 278-282.	0.6	18